What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity

WSW, NY, July 22nd, 2026, FinanceWire

Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq: VRTX) agreed to pay on July 6, 2026, to acquire Crinetics Pharmaceuticals (Nasdaq: CRNX) at $85.00 per share, roughly a 101% premium to the prior close.

Consider what Vertex is buying: PALSONIFY, the first and only once-daily oral therapy approved for adults with acromegaly, a rare pituitary disorder, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia. Vertex estimates the two products could generate approximately $5 billion in combined peak annual sales.

The strategic lesson is bigger than “an oral drug for a rare disease.” Oral administration can dramatically amplify the value of a clinically validated rare-disease therapy, particularly when it replaces burdensome injections and makes lifelong treatment more practical. Crinetics showed that extraordinary value is created by applying differentiated receptor pharmacology and a better route of administration to proven endocrine mechanisms.

It was not an isolated bet. In April 2026, Neurocrine Biosciences agreed to acquire Soleno Therapeutics for roughly $2.9 billion, chiefly for VYKAT XR, an oral therapy for hyperphagia, the relentless, hard-to-control hunger that defines Prader-Willi syndrome. The drug had been on the market barely a year.

The Soleno acquisition lands closest to Palatin. It validates the commercial value of treating hyperphagia in Prader-Willi syndrome, one of the core patient populations Palatin intends to address, albeit through a different mechanism.

What Palatin is building

Palatin Technologies (Nasdaq: PTN) is developing next-generation MC4R agonists for severe, biologically driven forms of obesity in which hunger, satiety and energy balance are disrupted at the level of the hypothalamus. Its initial focus is hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome, rare conditions marked by persistent hyperphagia, impaired satiety and substantial lifelong medical burden.

These are not smaller versions of common obesity. In acquired hypothalamic obesity, the brain circuitry governing appetite and energy expenditure may be damaged by a tumor or its treatment. In Prader-Willi and Bardet-Biedl syndromes, genetic abnormalities disrupt the pathways that regulate hunger and body weight. GLP-1 therapies such as Wegovy and Mounjaro help some patients, but they do not directly target MC4R, the downstream receptor Palatin is seeking to activate, and none is approved specifically for these conditions.

Palatin has translated this biology into an approved medicine before: its bremelanotide became Vyleesi, the first melanocortin-receptor agonist approved by the FDA, in 2019.

Rhythm proved the mechanism, and set the bar

Rhythm Pharmaceuticals (Nasdaq: RYTM) got there first. Its drug IMCIVREE (setmelanotide) activates the same receptor Palatin targets and is approved in the U.S. for acquired hypothalamic obesity and several rare monogenic or syndromic forms of obesity. Targeting MC4R for severe rare obesity is no longer a hypothesis; the mechanism has been clinically, regulatorily and commercially validated. Rhythm’s market capitalization now exceeds $7 billion (as of July 17, 2026).

That validation also set a benchmark. IMCIVREE requires daily subcutaneous injections, potentially for children and adults who may need treatment for life, and its label identifies hyperpigmentation, including darkening of skin and moles, as a common effect tied to activity at the related MC1R receptor. Rhythm itself is now developing weekly and oral MC4R agonists to move beyond that profile. Palatin must therefore differentiate not only from today’s daily injectable but from Rhythm’s advancing pipeline.

The pipeline and the calendar

Palatin has spent decades working on the melanocortin receptor system and is advancing two complementary preclinical MC4R programs: a next-generation, once-weekly injectable peptide and a next-generation oral small molecule. Its earlier oral compound, PL7737, earned Orphan Drug Designation for leptin-receptor-deficiency obesity; data from that program now inform the design, formulation and tolerability of the next-generation oral candidates.

Two milestones matter most. In the fourth quarter of 2026, Palatin is targeting an IND for the once-weekly peptide, which, if effective, could enter Phase 1 and cut dosing from daily to weekly. In the first half of 2027, it is targeting an IND and a Phase 1 study for the next-generation oral agonist, designed to eliminate injections entirely while sharply increasing MC4R-over-MC1R selectivity and reducing the off-target activity behind hyperpigmentation. In Palatin’s preclinical models, these compounds have shown improved selectivity, supporting the potential for greater potency, better tolerability and little-to-no hyperpigmentation.

The platform has also drawn outside interest: a research collaboration and license agreement with Boehringer Ingelheim on a separate melanocortin retinal program brought non-dilutive capital while the obesity work advances. The Boehringer collaboration does not directly validate Palatin's MC4R obesity candidates; it involves a separate MC1R-focused program.

A notable gap

Vertex agreed to pay roughly $10 billion for Crinetics. Neurocrine paid roughly $2.9 billion for Soleno. Rhythm carries a market capitalization above $7 billion. Palatin’s, as of July 21, 2026, was approximately $15 million.

That gap does may mean Palatin should be valued like those companies today. Its rare-obesity programs are early. The company must still complete IND-enabling work, enter human trials, establish pharmacologically active doses, demonstrate acceptable safety and efficacy, and finance years of additional development, and failure at any stage could materially impair the programs’ value.

What the gap does illustrate is the scale of value that can be created when validated rare-disease biology meets a meaningfully better product profile: once-weekly and oral dosing, greater selectivity, little-to-no hyperpigmentation and improved tolerability for lifelong use. If Palatin can carry those intended advantages from preclinical models into human safety and efficacy, it could emerge as a differentiated participant in a market whose commercial potential has already been proven.

Whether it can make that transition is the central question, and the source of both the opportunity and the risk.

Read this Next >>

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism (Nasdaq: RZLT)

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (Nasdaq: PVLA)

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates (Nasdaq: SLGL)

Recent News Highlights from Palatin (Nasdaq: PTN):

Palatin to Begin Trading on Nasdaq Stock Exchange

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Palatin Technologies, Inc. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article has not been reviewed or approved by the Issuer prior to publication and should not be considered an official communication of the Issuer.

Contact